The Axelyf Team

A man in a blue checkered blazer and white shirt posing against a dark grey background

Örn Almarsson, PhD

CEO, Co-founder

Portrait of a middle-aged man with short dark hair, wearing a navy blazer and light blue shirt, standing against a beige stone wall.

John Lucas, JD, PhD

Chief Counsel, Co-founder

Headshot of a smiling woman with black hair, wearing a dark green top against a white background.

Yan Xia, PhD

Head of Nanotechnology Formulations

Portrait of Daniel Omar Frimannson, Axelyf's Head of Nucleic Acids and Biology; a smiling middle-aged man with short dark hair and a beard, wearing a black suit jacket and white shirt, standing against a plain white background.

Daniel Omar Frímannsson, PhD

Head of Nucleic Acid Technologies and Biology

Arnar Sigurðsson, PhD

Principal Scientist

Distinguished Advisory Group

Axelyf is supported by experienced advisors spanning the full development pathway for RNA medicines — from regulatory, CMC and clinical pharmacology to computational sciences and nanotechnology. Their collective expertise directly informs Axelyf's platform development and therapeutic programs.

Gabor Butora, PhD – 30 years of pharmaceutical experience in medicinal and process chemistry, including nucleotide chemistry and lipid technologies

Daan Crommelin, PhD – prof. emeritus U. Utrecht in The Netherlands, nanotechnology and protein pharmaceuticals, complex drug product regulatory CMC expert, mRNA product advisor to the WHO

Dan Deaver, PhD – 40+ years academic and industry expertise, in vivo  pharmacology, toxicology consultant, including prodrugs, complex injectables

Jóhann E. Guðjónsson, MD, PhD – Arthur C Curtis Prof. of Skin Molecular Immunology, Prof. Dermatology; U. Michigan

Sushma Gurumurthy, PhD – Expert in oncology and immunology drug development including mRNA/LNPs

Magali B. Hickey, PhD – Seasoned Pharmaceutical R&D leader in drug delivery and nanotechnology product development

Eric Jacquinet, DVM, PhD, DABT – pharmacology, toxicology, pathology, preclinical discovery and drug development

Iain McFadyen, PhD – CD(S)O with a proven track record of building, leading, and developing impactful computational sciences and digital systems teams